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ABSTRACT
Objective: Suspected early-onset sepsis is a common diagnosis among neonates which warrants admission to the neonatal intensive care unit. 
Prolonged empiric antibiotic is the biggest concern and treatment duration is still controversial. Antimicrobial stewardship (AMS) program promotes 
early antibiotic de-escalation to reduce unnecessary antibiotic exposure and its implementation in the intensive care setting seems to be feasible. The 
primary objective of this review was to compare the existing guidelines and review the literature regarding choice and duration of empiric antibiotic 
in managing suspected early-onset neonatal sepsis.
Methods: Two Malaysian Ministry of Health guidelines were compared with guidelines from America (n=1), Australia (n=1), and United Kingdom 
(n=2). The literature search was conducted from January to June 2017 through open access journal and databases available at the author’s institution 
library (EBSCOHost, Ovid and Science Direct).
Results: All guidelines recommended similar antibiotics range and suggested to review treatment at 36– 72 h post antibiotic exposure. A total of 113 
abstracts and full articles were identified, and only 11 full-text articles published in English were related to the subject of interest. All studies show 
differences either in study design, choice of antibiotics, treatment duration or outcome measures; thus, a meta-analysis was not possible to be conducted. 
Conclusion: From this review, we found the potential to performed early empiric antibiotic de-escalation especially in clinically well-appearance 
neonates, and it is best to customize our guidelines based on local evidence which justify the need for more local research in this area.
Keywords: Neonate, Early onset sepsis, Guideline, Treatment, Duration.
INTRODUCTION
World Health Organization estimated that 6.9 million possible serious 
bacterial infections among neonates occurred in South Asia, Sub-Saharan 
Africa, and Latin America in 2012 [1]. Neonatal sepsis is the third common 
cause of neonatal death [1]. In Malaysia, neonatal deaths for the year 2000 
were reported at 1 per 2000 deaths [2]. Infection remains a significant 
contributing factor for mortality and morbidity in view of their immature 
immune system especially in premature neonates [3,4].
Early onset sepsis (EOS) is defined as sepsis occurring within 72 h of life [5] 
and caused by vertical transmission from mother to infant before delivery 
or during the delivery process [6-8]. Maternal infection during pregnancy 
commonly presented with chorioamnionitis and prevalence of neonates 
confirmed EOS was around 17.2% in mother confirm chorioamnionitis 
infection [9-11]. It is recommended in the guidelines to start the neonates 
with an empiric antibiotic if the mother diagnoses with chorioamnionitis 
which leads to overuse of antibiotic [12]. There is ongoing debating on 
how long to keep the antibiotic if the baby remains well [12].
From the global perspective, common microorganism related to EOS is 
Group B Streptococcus (GBS) [13,14]. However, after the wide exposure 
to intrapartum antibiotic prophylaxis (IAP) in mothers with GBS during 
pregnancy, the paradigm was shifted from prominently Gram-positive 
to Gram-negative organisms, especially Escherichia coli [15-17]. 
Ongoing microorganism culture and sensitivity surveillance are 
recommended to guide the choice of empiric antibiotics [18]. A recent 
local study reported that 77% from 22 proven EOS cases grew Gram-
positive organism mainly coagulase-negative staphylococci despite the 
IAP exposure and similar finding was reported elsewhere [19,20].
The role of empiric antibiotic in suspected EOS is crucial to reduce the 
morbidity and mortality risks [21-23]. This is a biggest challenge to the 
physician since signs and symptoms of neonatal sepsis are nonspecific and 
empiric antibiotic often used in neonates who are not infected [4,7,24]. 
It is pertinent that the choice of empiric antibiotic in suspected EOS 
must have both Gram-positive and Gram-negative bacterial coverage. 
The choice of antibiotic must be driven by guideline based on common 
microorganism in maternal genitourinary tract and their susceptibility 
patterns [25]. The combination of penicillin plus gentamicin, ampicillin 
plus gentamicin, and ampicillin plus cefotaxime is the most common 
combinations therapy used for empiric treatment in suspected EOS and 
listed as top 10 most common drugs utilization in neonatal intensive 
care unit (NICU) [4,25-28]. In some studies, they also reported the used 
of amikacin combinations in the management of suspected EOS [29,30].
A Cochrane review on antibiotic regimes for suspected EOS by Mtitimila 
and Cooke 2004 identified only two randomized control trials (RCTs) 
comparing effectiveness of timentin versus piperacillin plus gentamicin and 
ceftazidime versus gentamicin plus benzylpenicillin. Both studies showed 
no significant difference in primary outcome, mortality in 28 days and 
treatment failure defined as the need to change empirical antibiotic therapy. 
Nonetheless, both studies were from the 80’s and some of the antibiotics 
were no longer used at present; thus, findings from these studies were 
irrelevant to current practice [6]. The reviewer suggested to conduct more 
RCTs to conclude which antibiotic regimen is favorable. Thus, a review of 
more recent RCTs involving this topic is vital in providing more information 
regarding any antibiotic regimen used in the management of suspected EOS.
The duration of empirically initiated antibiotic is controversial when 
blood culture is sterile and clinical signs and symptoms resolve 
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rapidly [30]. Cotton and Smith et al. reported that through early initiation 
of empiric antibiotic could potentially save lives; however, there were 
limited data on treatment duration [31]. They also suggested that a lack 
of universal approach to interpreted infection biomarker in the critical 
phase of neonatal sepsis was the contributing factor for prolonged 
empiric antibiotic use [31,32]. Thus, proper guidelines are important to 
minimize both the overused and prolonged use of antibiotic as well as 
decrease the risks of resistance [33].
In recent years, Antimicrobial stewardship (AMS) programs have 
been promoted widely in Malaysia [34]. The purpose of this program 
is to ensure the appropriateness in the choice and administration of 
antibiotics. This program involves multidisciplinary team approach 
which includes doctors, pharmacists, microbiologists, and infection 
control. AMS role is to limit inappropriate antibiotic used and prevent 
multiresistant organism [35]. Besides, AMS also aim to improve 
patient outcomes and reduce health-care cost without compromising 
the quality of care [34,36]. However, AMS in NICU is not widely 
implemented in Malaysia due to limited expertise in pediatric infectious 
disease; nevertheless, the concept can be adopted.
Early antibiotic de-escalation is one of the approaches used by 
the AMS team to reduce the antibiotic misuse [37]. Antibiotic 
de-escalation ideally should not be protocolized but need to be 
performed by the doctor in charge of the patients in accordance 
with the clinical findings and organism identified from culture 
and sensitivity tests [38]. It is defined as a reduction of antibiotic 
spectrum by either reducing the number of antibiotics, stepping down 
to narrower spectrum or discontinuation of all antibiotics if there is 
no obvious infection [39-41]. Antibiotic de-escalation was feasible 
to be implemented in critical care patients with pneumonia, intra-
abdominal infection and septic shock without increasing mortality 
risk [40,42-46].
The appearance of a clinical pharmacist in NICU has been developed 
tremendously with the important role to ensure pharmacotherapy 
optimization, appropriateness, and safety [47]. The physician’s 
acceptance toward pharmacist intervention in NICU was reported 
high especially in the appropriateness of drug dose and frequency 
[48]. Hence, the presence of a clinical pharmacist in NICU can 
be fully utilized by working together with a physician to ensure 
appropriateness of empiric antibiotics choice and duration and 
helping the de-escalation process in suspected EOS.
The purpose of this review is to compare Malaysian guidelines with 
other established guidelines and conduct a review on recent supporting 
evidence from published articles on empiric antibiotic choice and 
treatment duration in suspected early-onset neonatal sepsis.
METHODS
Established guidelines available online were compared with local 
published guidelines. Choice of treatment and duration recommended 
by guidelines was extracted and presented in a comparison table.
A literature search to identify published articles related to the 
management of suspected EOS was done from June to December 2017. 
In this review, we included all types of study design that described 
antibiotics choice and treatment duration used in EOS. The searched 
structure involved using Boolean operators for a combination of 
following terms: EOS, neonatal, treatment, duration, guideline, and 
management.
The search was limited to publication from the year 2000 and above. 
The list of title and abstract from open access journal and local 
university electronic databases (EBSCOHost, Ovid and Science Direct) 
was screened, and duplications were removed. Full-text articles written 
in English and defined EOS as suspicion of neonatal sepsis within 3 days 
after birth regardless of the gestational age were retrieved and included 
in the review.
Quality of evidence was assessed using Cochrane Risk of Bias tool 
and Newcastle-Ottawa Quality Assessment Scale. The information 
regarding empiric antibiotic regimens, treatment duration, and 
treatment outcome were then extracted from articles and compared 




Two local guidelines by the Ministry of Health Malaysia (MOH), namely 
3rd Pediatric Protocol [49] and 2nd National Antibiotic Guideline (NAG) 
(2014) [50] were reviewed. Treatment for suspected early-onset 
neonatal sepsis and duration to review was extracted and documented 
in Table 1. Four other guidelines from Australia (n=1), United State of 
America (n=1), and United Kingdom (UK) (n=2) were identified and 
compared.
The first line empiric antibiotic treatment suggested in local guideline was 
intravenous (IV) C-penicillin or ampicillin in combination with gentamicin 
which is in concordance with the Australian guideline [51]. The American 
guideline [30] suggested the use of IV ampicillin in combination with 
aminoglycosides or third-generation cephalosporin as an alternative to 
aminoglycosides whereas UK guidelines [52,53] suggested IV C-penicillin 
in combination with Gentamicin. IV cefotaxime stated as an alternative 
treatment in most guidelines to cover meningitis due to its excellent 
cerebrospinal fluid penetration properties [30,50-53].
Table 1: Guidelines comparison on choice of antibiotic for EOS
Guideline Treatment Duration
Local guideline
3rd Pediatric Protocol MOH [49] IV C-penicillin or ampicillin plus gentamicin Trace culture results after 48–72 h. Adjust 
antibiotics according to the results
2nd NAG MOH IV C-penicillin or ampicillin plus gentamicin
or ampicillin plus cefotaxime (alternative)
Review at 36 h with culture result
International guideline
South Australian perinatal practice 
guideline [51]
IV C-penicillin or ampicillin plus gentamicin Duration of treatment depends on clinical 
circumstances but is at least 48 h
(AAP) [30] IV ampicillin plus aminoglycoside  
(usual gentamicin as synergy)
or IV ampicillin plus 3rd generation 
cephalosporin (Cefotaxime)
Empiric antibiotic duration remains 
controversial. Suggest to off at 48 h if the 
probability of sepsis is low
NICE UK[52] and NHS UK [53] IV C-penicillin plus gentamicin Consider stopping antibiotics 36 h after 
starting antibiotics if blood culture is negative, 
and initial suspicion of infection was not strong
AAP: American academy of pediatrics, MOH: Ministry of Health, UK: United Kingdom, NAG: National Antibiotic Guideline, NICE: National Institute for Health and Care 
Excellence, NSH: National Health Service, IV: Intravenous, EOS: Early-onset sepsis
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Duration to review the empiric antibiotic treatment varied between 
guidelines. Only 3rd Pediatric Protocol [49] stated to review treatment 
48–72 h whereas Australian and American of Pediatrics (AAP) 
guidelines recommend reviewing at 48 h. Both UK guidelines (NICE 
and NHS) suggested reviewing treatment as early as 36 h postempiric 
antibiotic exposure in concordance with the Malaysian NAG [50,52,53].
All guidelines suggest for blood culture to be taken before empiric 
antibiotic administration and treatment duration should be reviewed 
with the presence of blood culture result [30,50-53]. NICE guideline 
specifically recommends measuring C-reactive protein (CRP) 
concentration at sepsis presentation and to repeat measurement 
18–24 h after the presentation to guide the treatment duration [52].
The AAP guideline suggests discontinuing antibiotic at 48 h if sepsis 
probability is low [30]. Whereas NICE recommends stopping therapy 
at 36 h if blood culture is negative, initial clinical suspicion of infection 
was not strong, baby’s clinical condition is reassuring with no clinical 
indicators of possible infection, and the trends of CRP concentration are 
reassuring [52].
Evidence-based compilation
The summary of the review process is shown in Fig. 1. A total of 113 
articles identified using searched keywords; suspected EOS, neonatal, 
treatment, duration, guideline, and management from open access 
journal and databases. After the title screening and article assessment, 
only 11 articles met the selection criteria and 102 were excluded from 
further assessment.
The review finding from 11 articles is summarized in Table 2. All 
articles were published between the year 2003 and 2016 with three 
RCTs, two prospective, and six retrospective studies. The largest sample 
population was 128,914 babies reported in a retrospective study by 
Clark et al. [25] and the smallest sample population was 59 babies 
reported in a RCT study by Tewari and Jain [54].
Out of 11 articles, seven were Caucasian populations, three Asian, 
and one African. Three studies used full-term or near-term neonates’ 
population and 4 studies used premature or low birth weight neonate’s 
population in their research. Remaining 4 studies reported their results 
in the form of gestational age range or comparison between full-term 
and premature neonates’ group. Meta-analysis was not possible in 
view of wide variations of study design and differences in population 
characteristics and study endpoints measured.
Choice of empiric antibiotic regime
Eleventh articles clearly stated the choice of antibiotics used in their 
study. Only 6 articles compared endpoint of two different treatments. 
Four studies compared two different treatment combinations (ampicillin 
plus gentamicin vs. piperacillin-tazobactam; ampicillin plus gentamicin 
versus C-penicillin plus gentamicin; ampicillin plus cefotaxime versus 
ampicillin plus gentamicin; and ampicillin plus aminoglycosides versus 
C-penicillin plus aminoglycosides) [21,25,26,55]. One study compared 
two different monotherapies (amikacin vs. piperacillin-tazobactam) [54].
Two studies compared ampicillin plus gentamicin and penicillin plus 
gentamicin regime; one RCT and one prospective study [21,26]. The 
outcome of both studies showed no significant difference in mortality 
endpoint between regimes [21-26]. The RCT study also reported that 
treatment failure defined as antibiotic escalation within 72 h and 
mortality in 7 days of life was no differences between both regimes [26].
Prolonged postnatal exposure to an empiric antibiotic is a risk factor 
for developing necrotizing enterocolitis (NEC) [57,61]. Piperacillin-
tazobactam showed less NEC and diaper rash effect as compared to 
ampicillin plus gentamicin [55] and similar efficacy with amikacin 
monotherapy [54] in neonates at risk of EOS.
One retrospective study comparing ampicillin plusc or gentamicin 
regimes showed that concurrent use of cefotaxime was an independent 
factor associated with increased risk of neonatal death [25]. In addition, 
prolonged or extensive use of third-generation cephalosporin has been 
identified as a risk for invasive candidiasis. Routine use of cefotaxime 
for treatment of EOS had led to reports on rapid development of 
resistance [30].
From the review, we found that first-line empiric antibiotic regime 
suggested in the guidelines (ampicillin plus gentamicin or penicillin 
plus gentamicin) seems to be favorable with similar effectiveness. 
Piperacillin-tazobactam has the potential to be an alternative treatment 
in the management of suspected early-onset neonatal sepsis [54,55]. 
The use of cefotaxime antibiotic, however, should be limited due to 
undesirable outcome [62].
Treatment duration with antibiotics for EOS
Nine studies reported the treatment duration in mean (standard 
deviation) day [58,59], median interquartile range day [21,25,55,60] or 
day [3,56]. The longest treatment duration for suspected EOS reported 
in this compilation was ≥7 days [3] and the shortest was 3 days or 
less [3,57]. Two studies did not mention clearly the treatment duration 
used in their study [26,54].
Three studies compared endpoint of similar treatment combinations 
(ampicillin plus amikacin, ampicillin plus gentamicin, and ampicillin 
plus aminoglycosides) with different treatment durations (3-day 
vs. 5-day; <5-day vs. ≥5-day; ≤3-day vs. ≥7-day) [3,56,57]. One study 
used three antibiotics combination (amoxicillin plus cefotaxime plus 
amikacin) and compared the outcome based on treatment duration [58]. 
Other studies described the treatment duration without comparing 
them [21,25,55,59,60].
Cotten et al. proved that prolonged treatment >5 days was associated 
with NEC [57]. Both Cordero and Ayers and Labenne et al. reported 
that early discontinuation of empiric antibiotic when blood culture 
is negative can reduce unnecessary antibiotic exposure without 
compromising clinical outcome (mortality related to EOS and late-
onset sepsis). Thus, it will not increase the risk of infectious relapse and 
may decrease the incidence of late-onset sepsis [3,58].
Ibrahim et al. reported that giving an empiric antibiotic for <4 days will 
provide prevention of early-onset neonatal sepsis up to 89–95% [59]. 
Pasha et al. reported that treatment duration of 3 days versus 5 days 
showed no difference in treatment failure for both duration [56].
In this review, we can conclude that by giving a shorter treatment 
duration (3 days) the desired outcome will not be compromised. 
Besides, early discontinuation when blood culture is sterile may reduce 
empiric antibiotic overuse and cut cost [60].Fig. 1: Flow chart of the article review process
Records identified through open access 
journal and databases search (n=113)
EBSCO Host (51), Ovid (16), Science 
Direct (42) and open access (4)
Records after duplication removed (n=89)
Full -text article in English language 
included in the review
(n=11)
Full -text article in foreign 
language excluded (n=1)
Records excluded after 
title/abstract analysis (n=77)
Full -text article with related title retrieved 
for further assessment (n=12)
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DISCUSSION
Neonates are a vulnerable population and prone to infections. 
Suspected early-onset infection is the most common diagnosis in 
NICU, and the empiric antibiotic is crucial at this point [5]. RCT in 
the neonatal population is limited due to ethical reasons [6]. Hence, 
ongoing microorganism culture and sensitivity patterns surveillance 
are important to establish local antibiotic guideline [18,63].
Bacterial profile and antimicrobial susceptibility pattern of a unit can 
guide effective empiric antibiotic choices; however, it may vary from 
center to center depending on the IAP practice [15]. A recent local data 
reported that nearly 80% of proven EOS had Gram-positive organism 
isolated from the blood culture [19] and most showed sensitivity 
toward the recommended first-line empiric antibiotics, C-penicillin 
plus gentamicin [59].
Established antibiotic guidelines are important to guide the duration of 
treatment and subsequently influence treatment decision making. By 
reviewing the probability of sepsis at 36 h [52] to 48 h [30] postempiric 
antibiotic exposure, it potentially reduces the treatment duration by 
early de-escalation.
The probability of sepsis can be guided by pre-antibiotic initiation 
blood culture, full blood count (FBC), serial CRP, and procalcitonin 
(PCT) [64-66]. Blood culture and FBC are the most common and 
standard diagnostic measure for EOS in the most center [67]. Proven 
EOS with positive blood culture remains low at 3% possibly due to 
inoculation of only 0.5–1.0 ml of blood and it takes 24–48 h for the 
result [7,19,68,69]. In addition to the blood culture, FBC which includes 
white blood cell, platelet, and immature-total neutrophil ratio can be 
useful to rule out sepsis. However, FBC is less specific as compared to 
CRP [64].
CRP is a widely used biomarker with high specificity but low sensitivity 
because it also rises with non-infectious event; hence, it cannot be 
used alone [65,70]. Serial CRP at 24 h and 48 h can be helpful to assist 
decision-making whether to continue antibiotic despite sterile blood 
culture and normal FBC [31,71,72]. PCT biomarker is more specific and 
sensitive than CRP. PCT: CRP ratio can differentiate proven sepsis more 
clearly, however, PCT test is rather costly [65,73,74].
Guidelines should also consider the local resources and availability on 
providing laboratory results within the timeline of 36–48 h [40,73]. 
In certain places with limited resources, it may be difficult to provide 
efficient laboratory results [31]. Hence, longer time was needed to 
review sepsis probability and lead to the prolonged antibiotic used [75]. 
Recent study suggested the used of cord blood to detect CRP elevation 
as a potential biomarker tools for EOS diagnosis confirmation may 
potentially reduce the unnecessary antibiotic exposure [76].
Combination therapy with Gram-positive and Gram-negative antibiotic 
coverage was recommended by all the guidelines to treat suspected 
EOS [30,49-52]. One study in Boston discovered the potential of early 
antibiotic withdrawal in premature neonate once blood culture sterile 
and recommended as one of the antibiotic stewardship opportunity [68]. 
Meanwhile, early de-escalation by reducing the number of antibiotics 
within 72 h generally will reduce the risk of resistance and reduce the 
cost [39]. It is also safe to be implemented in critical care patients [38,77].
In Malaysia, the common causative EOS infection despite the extensive 
IAP used was Gram-positive organisms, and similar finding was also 
reported in other studies [19-20,78]. Hence, early withdrawal of Gram-
negative antibiotic coverage (aminoglycoside or cephalosporin) as 
antibiotic de-escalation strategy can potentially be implemented in 
clinically well-appearance neonate’s while waiting for laboratory result 
confirmation. Shorten the unnecessary aminoglycosides exposure to 
the neonate will reduce the risk of renal and ototoxicity whereas limited 
used of cephalosporin will reduce the risk of resistance and invasive 
candidiasis [1,30, 75,79,80].
Furthermore, early de-escalation and shorter treatment duration in 
suspected EOS did not increase the risk of treatment failure, and there 
is a reduced risk of late-onset sepsis, NEC and mortality as reported 
by previous studies especially in premature neonates [3,57,58,75]. 
Empiric antibiotics discontinuation by 48 h of life in well-appearing 
term neonates with chorioamnionitis mother are strongly suggested 
in the guideline, and it can reduce the antibiotic exposure proven by a 
recent study conducted by Grant et al. [81,82]. It is suggested to continue 
reviewing future published evidence and produce a systematic review 
meta-analysis whenever possible.
CONCLUSION
There were differences in the guidelines and practices in managing 
suspected early-onset neonatal sepsis. However, the current review 
does not warrant the conclusion of which antibiotic regimes are 
superior and what is the ideal empiric antibiotic duration due to lack 
of high-quality RCT study. The best is to customize our guidelines based 
on local evidence which justify the need for more local research in this 
area.
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